Delphia (USA)’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-10,552
Closed -$131K 348
2022
Q4
$131K Sell
10,552
-914
-8% -$12.9K 0.15% 230
2022
Q3
$160K Sell
11,466
-5,643
-33% -$90.9K 0.18% 215
2022
Q2
$236K Buy
17,109
+756
+5% +$12.1K 0.16% 242
2022
Q1
$266K Buy
16,353
+3,523
+27% +$55.2K 0.2% 196
2021
Q4
$209K Buy
+12,830
New +$216K 0.22% 211

Other funds holding ICPT

Delphia (USA)'s ICPT Position: Q1 2023 in Review

Delphia (USA) sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q1 2023, closing a stake of 10,552 shares — an estimated $131K sold.

Delphia (USA) first reported a position in ICPT in Q4 2021 and held it in 5 quarters. The position peaked at $266K in Q1 2022. 144 funds tracked by Wall St. Rank hold ICPT as of Q1 2023.

  • Delphia (USA) reported no remaining Intercept Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
  • Delphia (USA) sold 10,552 Intercept Pharmaceuticals, Inc. shares in Q1 2023, an estimated $131K.
  • Delphia (USA) first reported a position in Intercept Pharmaceuticals, Inc. in Q4 2021 and held it in 5 quarters.
  • Delphia (USA)'s Intercept Pharmaceuticals, Inc. position peaked at $266K in Q1 2022.
  • 144 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q1 2023.

Based on Delphia (USA)'s 13F filing for Q1 2023, filed 15 May 2023.